Theravance Biopharma reports Q1 EPS (27c) vs. (24c) last year

Reports Q1 revenue $15.4M, consensus $15.57M. Cash, cash equivalents and marketable securities totaled $130.9M as of March 31, 2025. “As we begin the year, we remain focused on delivering against our operational priorities for YUPELRI and ampreloxetine,” said CEO Rick Winningham. “Our commercial partnership with Viatris delivered solid YUPELRI sales growth, aided by a strong performance in the hospital setting. Trelegy delivered another excellent quarter and our clinical team advanced Cypress enrollment, which is now nearing completion. Our interactions with the MSA community continue to highlight the urgent need for new treatments for symptomatic nOH and ampreloxetine’s potentially significant value to patients, caregivers and providers, underpinning our motivation to complete CYPRESS enrollment and share our results.”